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NEUEROPILIN-2 IN PANCREATIC CANCER AND SEMAPHORIN-3F AS A 
TREATMENT 
 
 
XIAORAN LI 
 
ABSTRACT 
 
INTRODUCTION: 
Pancreatic cancer remains the fourth leading cause of cancer-related deaths with 
approximately 5% five-year survival and 3 months of median survival. The survival rate 
of pancreatic cancer has not improved substantially over the past 40 years. Therefore, a 
novel potential treatment for pancreatic cancer is urgently needed. Recently, a cell 
surface receptor, Neuropilin-2 (NRP-2), was found to competitively bind either 
stimulatory angiogenic ligands such as vascular endothelial growth factor-A (VEGFA) or 
inhibitory class 3 Semaphorin-3F (SEMA3F) ligands. Knowing that angiogenesis is 
necessary for pancreatic tumor growth, elucidating the role of NRP2 in angiogenesis may 
lead to curative treatment for pancreatic cancer. 
 
OBJECTIVES: 
Previously, NRP-2 has been shown to be expressed by human cells of pancreatic 
ductal adenocarcinoma (PDAC), one of the most lethal forms of pancreatic cancer. 
Additionally, knockdown of NRP-2 in vivo inhibited PDAC tumorigenesis. In our current 
		 vii 
study, we aimed to investigate the role of endothelial cell derived-Nrp-2 in PDAC-
associated tumor angiogenesis. Furthermore, we studied the efficacy of SEMA3F as a 
potential inhibitory factor for pancreatic tumor growth. 
 
METHODS: 
To investigate the role of Nrp-2 in tumor-derived angiogenesis, we injected 
Panc0H7 cells, a C57BL/6 syngeneic mouse PDAC cell line, orthotopically into the 
pancreas of Nrp-2+/+, Nrp-2+/-, and Nrp-2 -/- mice and compared tumor growth and 
angiogenesis. We next injected control adenovirus (Ad-control) or SEMA3F adenovirus 
(Ad-3F), which actively encodes SEMA3F in vivo, followed by orthotopic injection of 
Panc0H7 cells into C57BL/6 mice three days later. We studied the efficacy of SEMA3F 
as a potential treatment for pancreatic cancer by comparing the tumor growth and tumor-
associated angiogenesis of the two groups of adenovirus-treated mice. 
 
RESULTS: 
Our results showed that Panc0H7 tumors were significantly smaller in Nrp-2-
deficient mice as compared to that of Nrp-2-intact mice. Furthermore, tumor microvessel 
density was significantly lower in Nrp-2-knockout mice compared to wild-type mice, 
while there was no difference in tumor weight or angiogenesis between wild-type and 
Nrp2 heterozygous mice. Our results also demonstrated that pancreatic tumors harvested 
from SEMA3F-treated mice were significantly smaller than the tumors from the control-
		 viii 
treated mice. Furthermore, micrometastases were detected in the livers of mice treated 
with Ad-control but not in the Ad-3F group. 
 
CONCLUSIONS: 
Taken together, our results suggested that NRP2 might facilitate in vivo 
angiogenesis and tumor growth. Furthermore, SEMA3F could be a potential treatment to 
inhibit the growth and metastases of pancreatic tumors. 
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INTRODUCTION 
 
Pancreas 
 The pancreas is an important component of the digestive system that is located 
behind the stomach and above the small intestine in the upper left abdomen (Khan, 2014). 
Extending horizontally in the abdomen, the wide end of the pancreas is called the head, 
which is positioned at the juncture between the stomach and the duodenum of the small 
intestine. The head is also the most innervated part and the most common location of 
cancer (He et al., 2016). The tail of the pancreas is narrower than the head and extends to 
the left side of the abdominal cavity. The pancreas is composed of both endocrine and 
exocrine functions. The endocrine components of the pancreas, the islets of Langerhans, 
consist of alpha, beta, and delta cells that secrete glucagon, insulin, and somatostatin 
(Constanzo, 2006). Constituting approximately 4.5% of the pancreas volume, the 
endocrine functions of the pancreas are critical for maintaining the homeostasis of the 
glucose level in the blood and neurotransmission (Ionescu-Tirgoviste et al., 2015). About 
85% of the mass of the pancreas functions as an exocrine gland that secretes pancreatic 
juice containing multiple enzymes facilitating nutrient absorption in the small intestine 
(Fisher, 2009). Enzymes secreted by the acinar cells in the pancreas help digest ingested 
protein, carbohydrates, and lipids (Fisher, 2009). Therefore, an intact and functional 
pancreas is critical for maintaining physiological homeostasis.  
 
 
		 2 
Vascular Endothelial Growth Factor (VEGF) and Angiogenesis 
 A functional network of blood vessels is pivotal for physiological functions and 
homeostasis, and VEGF is fundamental for the development of vascular supply (N. 
Ferrara & Davis-Smyth, 1997). VEGF induces vascular permeability, which is important 
for angiogenesis associated with tumors and wounds (Connolly et al., 1989). The human 
VEGF gene is spanning over 14 kilobases. (Tischer et al., 1991). There are five encoded 
molecules in the VEGF family, which include VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
and placental growth factor (PIGF) (Tischer et al., 1991). The VEGF-A gene encodes 4 
isoforms, given rise by alternative splicing, which include VEGF165, the major isoform of 
VEGF-A, VEGF121, a slightly acidic form that cannot bind heparin, VEGF189, and 
VEGF206 (Tischer et al., 1991). VEGF-A is mainly responsible for vascular angiogenesis, 
and any defect in the VEGF-A allele results in embryonic failure (N. Ferrara et al., 1996). 
Angiogenesis could also be induced by VEGF-B and PIGF, but they have minor roles 
compared to VEGF-A (Scotney et al., 2002). On the other hand, VEGF-C is essential for 
lymphangiogenesis and the active form is generated from proteolytic cleavage, as is 
VEGF-D (Karkkainen et al., 2004; McColl et al., 2007). Taken together, in addition to 
inducing angiogenesis, VEGF is also responsible for inhibiting smooth muscle 
proliferation, inhibiting inflammatory response, and promoting lymphangiogenesis 
(Zachary, 2001). 
The effects of VEGF are transduced through cell membrane receptors that include 
VEGF receptor VEGFR-1, VEGFR-2, and VEGFR-3 (S. Takahashi, 2011). All subtypes 
of VEGFR contain a seven immunoglobulin-like extracellular domain, which is 
		 3 
responsible for VEGF binding, and a cytoplasmic component, which is a tyrosine kinase 
domain (Ferrara, Gerber, & LeCouter, 2003; Shibuya et al., 1990). While VEGFR-1 and 
VEGFR-2 are found on some tumor cells and VEGFR-1 is also discovered on 
macrophages and monocytes, VEGFR-3 is mainly found on lymphatic endothelial cells 
(Takahashi, 2011). The three subtypes of VEGFR have various affinities to different 
proteins in the VEGF family. While VEGF-B and PIGF could only bind VEGFR-1, 
VEGF-A binds both VEGFR-1 and VEGFR-2 (Ferrara et al., 2003). VEGF-C and 
VEGF-D bind to VEGFR-3 in their proform and to VEGFR-2 in their cleaved form 
(Figure 1) (Ferrara et al., 2003).  
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Although VEGFR-1 has higher affinity to VEGF-A binding compared to 
VEGFR-2, it is surprising to see that mice lacking the tyrosine kinase domain of VEGFR-
1 possess normal vasculature, meaning that VEGFR-1 has a relatively minor role in 
stimulating normal angiogenesis, although VEGFR-1 has been shown to induce tumor 
angiogenesis (Clauss et al., 1996; Hiratsuka, Minowa, Kuno, Noda, & Shibuya, 1998). 
Figure 1 | VEGF Binding with VEGFRs. VEGFRs bind to specific ligands from the 
VEGF family. VEGFR-1 binds VEGF-A, VEGF-B and PIGF. VEGFR-2 also binds 
VEGF-A (and cleaved VEGF-C). Although VEGF-A has lower affinity to VEGFR-2 than 
VEGFR-1, VEGFR-2 is more essential for angiogenesis and VEGFR-1 acts as a decoy 
receptor. VEGFR-3 is mainly responsible for lymphangiogenesis. Ligands for VEGFR-3 
include VEGF-C and VEGF-D. Adapted from Takahashi, 2011. 
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VEGFR-2 is alternatively named KDR in humans or Flk-1 in mice, primarily responsible 
for responding to VEGF cytokines and promoting angiogenesis under both physiological 
and pathological conditions (Takahashi, 2011). Flk-1-deficient mice resulted in 
embryonic lethality, confirming that VEGFR-2 is essential for vasculature formation 
(Shalaby et al., 1995). Different to VEGFR-1 and VEGFR-2, VEGFR-3 expression on 
lymphatic endothelial cells is primarily responsible for lymphangiogenesis responding to 
VEGF-C and VEGF-D (Alitalo & Carmeliet, 2002; Veikkola et al., 2001). While 
VEGFR-1 has weak autophosphorylation upon VEGF stimulation, VEGFR-2 passes 
down angiogenic signals via the PLCγ-PKC-MAPK pathway and induces angiogenesis 
downstream once bound to VEGF (T. Takahashi, Ueno, & Shibuya, 1999; T. Takahashi, 
Yamaguchi, Chida, & Shibuya, 2001). The importance of VEGFR-2 in regulating 
angiogenesis makes VEGFR-2 a crucial target in tumor angiogenesis. 
 
Pancreatic Cancer 
 Pancreatic cancer remained the fourth leading cause of cancer-related deaths. In 
the year of 2015, 53070 new cases and 41780 deaths related to pancreatic cancer were 
found in the United States (Siegel, Miller, & Jemal, 2015). Increased age, smoking, 
obesity, and inherited genes are all risk factors that contribute to the occurrence of 
pancreatic cancer (National Cancer Institute, 2014). Pancreatic ductal adenocarcinoma 
(PDAC) is one of the most lethal malignancies of all pancreatic cancer cases, with 
approximately 5% five-year survival rate and 3 months of median survival (Worni et al., 
2013). Currently, pancreatectomy followed with adjuvant chemotherapy serves as the 
		 6 
standard approach in treating primary pancreatic cancer, increasing the overall survival 
rate to 20% and median survival to 23 months (Kaiser, 1985; Stark et al., 2016). 
However, more than 80% of the diagnosed PDAC patients are not eligible for surgery, as 
most PDAC diagnosis are made at a late stage (Perkhofer, Ettrich, & Seufferlein, 2015). 
The survival rate of pancreatic cancer has not improved substantially over the past 40 
years. Therefore, a novel potential treatment for pancreatic cancer is urgently needed.  
 
The Neuropilin Family 
STRUCTURES 
Neuropilins (NRP) are a family of cell surface receptors originally named for their 
role in neuronal guidance during embryonic development, via neuropilin/semaphorin III 
(SEMA3)-mediated chemorepulsive signals (Kitsukawa et al., 1997). Recently, NRP was 
discovered to possess pleiotropic functions. NRPs can act as coreceptors for VEGF with 
VEGFR, in addition to its role in peripheral nerve development (Oh et al., 2013; Soker, 
Takashima, Miao, Neufeld, & Klagsbrun, 1998).  
There are two NRP genes, NRP1 (At1g74560) and NRP2 (At1g18800) spanning 
over 120 and 112 kilobases on chromosomes 10p12 and 2q34, that encode protein 
receptors NRP-1 and NRP-2, respectively (M. Rossignol, Beggs, Pierce, & Klagsbrun, 
1999; Zhu et al., 2006). Both NRP1 and NRP2 genes contain 17 exons (Klagsbrun, 
Takashima, & Mamluk, 2002). NRP-1 and NRP-2 are two highly conserved homologous 
structures of the NRP family (Mireille Rossignol, Gagnon, & Klagsbrun, 2000). Both 
NRP-1 and NRP-2 have a transmembrane form and a soluble form. Transmembrane 
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NRP-1 and NRP-2 are 130-140 kDa glycoproteins with 44% homology at the amino acid 
level (Mireille Rossignol et al., 2000). The extracellular domain of both NRP-1 and NRP-
2 consists of two CUB motifs named domain a1 and a2, two domains homologous to 
coagulation factor V and VIII named b1 and b2, and a MAM domain designated as 
domain c (Figure 2) (Kawakami, Kitsukawa, Takagi, & Fujisawa, 1996; Takagi et al., 
1991). Transmembrane NRP-1 and some isoforms of NRP-2 also share homology in the 
transmembrane domain and the C-terminal cytoplasmic domain.  
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Soluble NRPs (sNRP) are truncated NRP receptors with molecular weight of 60-
90 kDa (Gagnon et al., 2000; Panigrahy et al., 2014). Containing the a (CUB) domain and 
the b (coagulation factor homology) domain, soluble NRP-1 and soluble NRP-2 still 
function as receptors for VEGF and SEMA3 ligands (Gagnon et al., 2000; F. Nakamura, 
Tanaka, Takahashi, Kalb, & Strittmatter, 1998). Similar to soluble VEGFR, soluble NRP 
Figure 2 | Domains on NRPs. Both NRP-1 and NRP-2 contain a1, a2, b1, b2, 
and a c domain on the extracellular component of the receptor. NRP-1 and NRP-
2a also contain a PDZ domain on the intracellular component. Adapted from 
(Nakamura & Goshima, 2002) 
 
		 9 
could bind circulating VEGF and suppress angiogenesis by VEGF withdrawal (Gagnon 
et al., 2000; Kendall & Thomas, 1993). For example, s12NRP-1 could inhibit VEGFR 
phosphorylation induced by VEGF165 in vitro, and overexpression of s12NRP-1 in vivo 
could lead to increased tumor apoptosis and vessel damage in rat prostate carcinoma 
(Gagnon et al., 2000). In addition, treatment involved with sNRP-1 has also been shown 
to reduce tumor progression by inhibiting the invasive behaviors of lung cancer cells 
(Hong et al., 2007).  These data suggest that sNRPs could sequester VEGF and thus 
potentially prevent tumorigenesis induced by transmembrane NRPs (Geretti, Shimizu, & 
Klagsbrun, 2008). 
NRP-2a and NRP-2b, generated by alternative genetic splicing, are two isoforms 
of NRP-2 (Mireille Rossignol et al., 2000). While NRP-2a and NRP-2b have identical 
extracellular domains, but heterogeneous transmembrane and cytoplasmic domains. The 
two isoforms are associated with nonoverlapping patterns of tissue distribution (Mireille 
Rossignol et al., 2000). The cytoplasmic domain of NRP-2a resembles that of NRP-1, as 
both receptors contain a 3-amino acid sequence, SEA, which binds the PDZ domain of 
the NRP-interacting proteins (NIP) (Cai & Reed, 1999). Without the SEA amino acid 
sequence, NRP-2b lacks the capacity of NIP interaction (Rossignol et al., 2000). 
However, NRP-2b does not function differentially to NRP-1 or NRP-2a in VEGF and 
SEMA3 binding, which is mainly carried out by the binding at the homogenous 
extracellular domain (Rossignol et al., 2000).  
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LIGANDS 
 NRP-1 and NRP-2 have variable affinity to angiogenic and inhibitory ligands. 
The VEGF binding sites reside in the b1 and b2 domains on the extracellular component 
of the NRPs (Kawakami et al., 1996). NRP-1 and NRP-2 both bind angiogenic factors 
from the VEGF family, but they are isoform-specific receptors that bind VEGF165 but not 
VEGF121, as the Exon 7 region on VEGF165 could interact with the b1 and b2 domains on 
NRPs, while there is no Exon 7 on VEGF121 (Mireille Rossignol et al., 2000; Soker, 
Gollamudi-Payne, Fidder, Charmahelli, & Klagsbrun, 1997; Soker et al., 1998). In 
addition, NRP-2 could specifically bind VEGF145 (Gluzman-Poltorak, Cohen, Herzog, & 
Neufeld, 2000. NRP-1 and NRP-2 are also receptors for PIGF-2 and VEGF-A, but they 
differ in the way that NRP-1 more specifically binds VEGF-B and VEGF-E, while NRP-
2 has higher affinity to VEGF-C and VEGF-D (Gluzman-Poltorak, Cohen, Herzog, & 
Neufeld, 2000; Makinen et al., 1999; Migdal et al., 1998).  
 NRPs also bind inhibitory ligands from the SEMA3 family and competitively 
inhibit the binding to VEGF, as the binding site for SEMA3 spans over the CUB domain 
as well as the b1 and b2 domains, overlapping with the VEGF binding domain (Geretti et 
al., 2008) (Figure 3). However, while NRP-1 and NRP-2 have similar extracellular 
components and both NRPs bind VEGF-3B/C/D with different affinity, the binding 
capacity of NRP-1 and NRP-2 differs in the way that NRP-1 binds SEMA3A, while 
NRP-2 binds SEMA3F (Raper, 2000).  
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Figure 3 | Ligands of NRP-1 and NRP-2. NRPs are receptors for the VEGF family and 
the SEMA3 proteins. NRP-1 and NRP-2 are isoform-specific that they bind to specific 
ligands. Ligands for NRP-1 include VEGF165, VEGFB, VEGFE, PIGF, and SEMA3A. 
NRP-2 has overlapping ligands with NRP-1 as NRP-2 also binds VEGF165. However, 
different to NRP-1, NRP-2 more specifically binds VEGF145, VEGFC, and SEMA3F. 
Adapted from Klagsbrun, Takashima, & Mamluk, 2002.  
		 12 
TISSUE DISTRIBUTION 
The two forms of NRPs have overlapping expressions on tissues, but each form 
also has various specific tissue distribution (Bielenberg, Pettaway, Takashima, & 
Klagsbrun, 2006). NRPs were first discovered on tissues in the nervous system. NRP-1 
was found to be expressed by sensory and sympathetic neurons, while NRP-2 was only 
found to present on sympathetic neurons (Chen, He, Bagri, & Tessier-Lavigne, 1998). On 
embryonic endothelium, NRP-1 is present on arterial endothelial cells, while venous and 
lymphatic endothelium only expresses NRP-2 (Bielenberg et al., 2006). Therefore, 
knocking out gene NRP1 leads to defects in arterial vessels, while NRP2 knockout might 
result in reduction in numbers of lymphatic vessels and capillaries (Kawasaki et al., 1999; 
Yuan et al., 2002). However, vasculature distribution of NRP-1 and NRP-2 is not fixed, 
and it can be influenced by factors such as hemodynamic forces from blood flow (Noble 
et al., 2004). Researchers have also observed expression of both NRP-1 and NRP-2 on 
endothelial cells of human umbilical veins in primary culture (Bielenberg et al., 2004).  
 NRP-1 and NRP-2 also have specific localizations. Tissue distribution of NRP1 
includes epidermal cells of skin, epithelial cells in the breast, uterus, endometrium, 
kidney, and lung (Gagnon et al., 2000; Klagsbrun et al., 2002). However, NRP-2 has 
different tissue localization as NRP-2 is expressed in hair follicles rather than in 
epidermal keratinocytes (Figure 4) (Bielenberg et al., 2006). Furthermore, NRP-2a is 
mainly found in placenta, liver, and lung, different to the pattern of expression of NRP-2b 
(Mireille Rossignol et al., 2000). 
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In a normal pancreas, NRP-2 is expressed on normal endocrine islets, co-localized 
with glucagon-secreting cells, but increased NRP-2 expression could be detected in 
multiple lines of pancreatic endocrine tumors, which means that NRP-2 might be a 
potential biomarker for endocrine tumors (Cohen et al., 2002). Different to NRP-2, NRP-
1 expression is be upregulated on pancreatic ductal cells unless PDAC takes place, which 
makes NRP-1 another possible biomarker for cancer (Fukahi, Fukasawa, Neufeld, 
Itakura, & Korc, 2004). NRP-1 and NRP-2 have been shown to be expressed by multiple 
human PDAC tumor cells. PDAC cells including AsPC-1 and BxPC3 express high levels 
of NRP-2 and Panc-1 expresses moderate level of NRP-2, while nonmalignant ductal 
Figure 4 | Tissue Distribution of NRP-1 and NRP-2. NRP-1 expression is 
found on epidermal cells in newborn skin, while NRP-2 is absent from the 
keratinocytes of the skin. Instead, NRP-2 is expressed on hair follicle cells. 
Adapted from Bielenberg et al., 2006. 
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cells show negative NRP-2 staining (Figure 5) (Dallas et al., 2008). In addition, AsPc-1, 
BxPC3, and Panc-1 all express NRP-1(Figure 5) (Dallas et al., 2008). Prevalent 
distribution of NRP-1 and NRP-2 in pancreatic tumors makes the NRPs potential targets 
for antitumor treatments. 
 
 
 
 
 
Figure 5 | NRP-1 and NRP-2 Expression in PDAC cell lines. Multiple PDAC 
cell lines express NRP-1 and NRP-2 on cell surface. AsPc-1, BxPC3, and Panc-1 
express NRP-1. AsPC-1 and BxPC3 express high levels of NRP-2 and Panc-1 
expresses moderate level of NRP-2, while nonmalignant ductal cells show 
negative NRP-2 expression. Adapted from Dallas et al., 2008. 
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In addition to pancreatic tumor cell lines, NRPs are also upregulated in other 
tumor cell lines. NRP-1 was seen to be upregulated in oral squamous cell carcinoma 
(Shahrabi-Farahani et al., 2016). In liver, NRP-1 is only present in the hepatic stellate 
cells and the liver endothelial sinusoidal cells in non-malignant tissues, but neither NRP-
1 nor NRP-2 expression has been detected in hepatocytes (Bergé et al., 2011; Zhuang et 
al., 2014). However, increased expression of NRP-1 on hepatocytes in malignant liver 
carcinoma was observed (Zhuang et al., 2014). Upregulation of NRPs makes them 
potential biomarkers for cancers with poor prognosis. 
 
SEMA3F 
 SEMAs were originally named “Collapsin” for its chemorepellent role discovered 
in neuronal guidance of axons (Kolodkin, Matthes, & Goodman, 1993; Y. Luo, Raible, & 
Raper, 1993). Later, roles of SEMAs in vascular development and inflammatory response 
were discovered in further experiments on mice and zebrafish that SEMAs were proved 
to be associated with cell adhesion, cell migration, angiogenesis, and lymphangiogenesis 
(Shi et al., 2000; Torres-Vázquez et al., 2004). There are eight classes in the family of 
SEMAs, and class III to VII could be found in vertebrates (Kolodkin et al., 1993). In our 
study, we focused on the SEMA class III (SEMA3), the only secreted SEMA in 
vertebrates that contains seven soluble molecules in its collection from SEMA3A to 
SEMA3G (Gherardi, Love, Esnouf, & Jones, 2004). SEMA3 proteins contain 
approximately 500 amino acids that can be divided into a single copy of N-terminal sema 
domain, one or more copies of a small cysteine-rich domain on the C-terminal side of the 
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sema domain, named the plexin-semaphorin-integrin domain, and an immunoglobulin 
loop (Kolodkin et al., 1993). Some SEMA3 proteins might fold into a 7-blade beta-
propeller structure that might be associated with SEMA3-NRP binding, discussed in 
greater details below (Gherardi et al., 2004).  
 
Signaling Pathways of NRPs 
 NRP-1 and NRP-2 are important receptors in regulation of tumor-associated 
angiogenesis as both NRP-1 and NRP-2 are involved in pathways related to the growth of 
blood vessels. NRP-1 could bind VEGF-A on Exon 7 (Soker et al., 1998). With binding 
capacity to VEGFR-2, VEGF-A could bridge NRP-1 and VEGFR-2, forming a complex 
that enhances the p38MAPK activation downstream and migration of endothelial cells 
(Kawamura et al., 2008; Soker et al., 1998). In addition, NRP-1 could also induce 
angiogenesis via platelet-derived growth factor binding or the NRP-1-ABL pathway, 
independent to the VEGF/VEGFR-2 pathway (Hu & Jiang, 2016). In multiple malignant 
tumors, upregulation of NRP-1 might also be responsible for tumor-associated 
angiogenesis. For example, the VEGF/NRP-1 axis was found to promote breast cancer by 
stimulating epithelial-mesenchymal transitions (M. Luo et al., 2016). In PDAC, 
researchers have observed increased angiogenesis induced by mucin-1 and NRP-1 
association (Zhou et al., 2016). In vivo, prostate tumors with induced NRP-1 expression 
were significantly larger than NRP-1 negative tumors (Figure 6) (Miao et al., 2000). 
However, although targeting NRP-1 seems promising in decreasing angiogenesis, NRP-1 
might not be an appropriate target for antitumor treatments as changes in levels of NRP-1 
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expression might lead to severe vascular defects, as both overexpression and deletion of 
NRP-1 lead to prenatal lethality during embryogenesis (Fujisawa & Kitsukawa, 1998).  
 
 
 
 
 
Figure 6 | NRP-1 Expression Associated with More Progressive Tumor Growth. 
Prostate tumors with induced NRP-1 expression had more progressive growth as the 
volume of the tumors with NRP-1 expression was significantly larger than that of 
tumors without NRP-1. Adapted from Miao et al., 2000. 
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Nrp-1 knockout mice demonstrated the critical role of Nrp-1 in angiogenesis, with 
embryonic lethality due to widely distributed defects in vascular patterning (Kawasaki et 
al., 1999). Complimentary to gene knockout, overexpression of Nrp-1 also resulted in 
embryonic lethality due to hyper-vascularization within the cardiovascular system 
(Kitsukawa, Shimono, Kawakami, Kondoh, & Fujisawa, 1995). It was thought that NPRs 
enhance the signal transduction induced by VEGFR, but they did not transduce signals 
themselves. However, recent findings on NRP-1suggested that NRP-1 might transduce 
signals without the presence of VEGFR (L. Wang et al., 2007).  
Similar to NRP-1, NRP-2 serves as a coreceptor with VEGFR-3 responding to 
VEGF, but NRP-2 deficiency is not incompatible with life, although deviations in 
capillaries and small lymphatics have been observed (Yuan et al., 2002). NRP-2 is also 
important in angiogenesis and tumor growth, as decreased Nrp-2 expression is correlated 
with reduce tumor growth in vivo (Figure 7) (Bielenberg, unpublished).  In our study, we 
observed that knockdown of NRP-2 expression in vivo inhibited PDAC tumorigenesis. 
We investigated the role of endothelial cell derived-Nrp2 in PDAC-associated tumor 
angiogenesis. Specifically, Panc0H7 cells, a C57BL/6 syngeneic mouse PDAC cell line, 
was injected orthotopically into the pancreas of Nrp2+/+, Nrp2+/-, and Nrp2 -/-mice. Our 
results showed that Panc0H7 tumors were significantly smaller in Nrp2-deficient mice as 
compared to that of Nrp2-intact mice. Furthermore, tumor microvessel density was 
significantly lower in Nrp2-knockout mice compare to wild type mice, while there was 
no difference in tumor weight or angiogenesis between wild type and Nrp-2 heterozygous 
mice. 
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Figure 7 | Suppressed Tumor Growth in Nrp-2 Knockout mice. B16F10 skin 
melanoma demonstrated suppressed tumor growth in Nrp-2 knockout mice compare 
to wildtype mice for up to 17 days. With presence of endothelial Nrp-2, B16F10 
tumors were significantly larger than tumors in Nrp-2 knockout mice. Adapted from 
Bielenberg, unpublished. 
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In addition to the role in promoting angiogenesis corecepting VEGF with 
VEGFR, NRPs could also induce cytoskeletal collapse through a group of receptors 
called Plexins, a gene family encoding 9 Plexins that bind the NRP-SEMA3 complex 
(Neufeld & Kessler, 2008). The NRPs form signaling complexes with type A Plexins or 
Plexin D1, and the signal transduction molecules in such complexes are the Plexin 
receptors (Neufeld & Kessler, 2008). Activation of Plexin A1 by SEMA3A and NRP-1 
leads to inhibition of the RhoA pathway, inhibiting the formation of actin filaments and 
thus reducing cell motility and migration (Neufeld & Kessler, 2008). Similar to NRP-1, 
NRP-2 association with Plexin A1 through SEMA3F also inhibits the RhoA pathway, 
leading to cell collapse in vitro (Figure 8) (Bielenberg et al., 2004). In vivo, SEMA3F 
competitively inhibits the binding of VEGF to NRP-2, resulting in reduced metastasis 
and reduced angiogenesis by repelling the sprouting of the blood vessels (Figure 9) 
(Bielenberg et al., 2004).  
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Figure 8 | Collapse of Actin Filament in Cells Treated with SEMA3F. NRP-2 
on HUVEC cells interacted with SEMA3F and induced downstream collapse of 
actin filaments. However, without SEMA3F treatment, the spindle-like actin 
filaments were observed in cytoplasm. Adapted from Bielenberg et al., 2004. 
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In this study, the efficacy of SEMA3F as a potential treatment for pancreatic 
cancer was investigated. To achieve high dose of SEMA3F at therapeutical levels, we 
used adenovirus as the delivering vehicle for SEMA3F. The capsid of therapeutical 
adenovirus type 5 is composed of 252 subunits, including 240 subunites alternatively 
named hexons (Stewart, 2002). The characteristic long protruding fibers on the capsid of 
the adenovirus could incorporte the adenovirus into cells, and the knob structure on the 
Figure 9 | Repelled Vasculature with SEMA3F Treatment. Tumors without 
SEMA3F treatment demonstrated rigorous vasculature within and surrounding 
the tumor area. However, SEMA3F-treated tumor was shown to repel the 
sprouting blood vessels away from the tumor area. Taken from Bielenberg et al., 
2004. 
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tip of the protruding fibers interacts with the coxsackievirus-adenovirus receptor on cell 
surface, internalizing adenovirus into cell cytoplasm by endocytosis (Zhang & Bergelson, 
2005). Adenovirus could be bridged to the liver through binding to the vitamin K-
dependent coagulation zymogens, which are able to bind receptors in the liver (Baker et 
al., 2007). The type 5 therapeutic adenovirus is lacking the E1 gene region, making the 
therapeutic adenovirus replication-deficient (Zhang & Bergelson, 2005). Therefore, the 
therapeutic adenovirus does not propagate in living organisms. The propagation of 
adenovirus would therefore require a cell line with E1 region to replicate (Gorziglia et al., 
1999). Human embryonic kidney (HEK) 293A cells, with presence of the E1 gene region, 
were therefore used for adenovirus propagation. Adenovirus incorporated with SEMA3F-
encoding gene was used to continuously deliver SEMA3F in our study. Previous studies 
have shown that adenovirus with SEMA3F loading might decrease tumor progression in 
U87MG primary glioblastoma (Figure 10). No research has been done on treating 
pacreatic tumors with Adenovirus-encoded SEMA3F and therefore our study focused on 
the efficacy of adenovirus-encoded SEMA3F in treating pancreatic tumors. We observed 
significantly smaller tumors in the SEMA3F-treated groups compare to the mcie injected 
with control adenovirus. We also believe the total angiogenesis was reduced in tumors 
treated with adenovirus-encoded SEMA3F. 
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Figure 10 | Decreased Tumor Growth with Treatment of Adenovirus-Encoded 
SEMA3F. The growth of U87MG glioblastoma was significantly reduced in mice 
treated with adenovirus encoding SEMA3F. However, the mice treated with control 
adenovirus had exponential tumor growth two weeks following tumor injection. 
Adapted from Bielenberg, unpublished. 
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SPECIFIC AIMS 
 
This study aimed to further understand the role of endothelial Nrp2 in pancreatic 
cancer-associated angiogenesis in C57BL/6 mice. Furthermore, we aimed to study the 
efficacy of SEMA3F as a potential treatment for pancreatic cancer.  
We previously know that B16F10 melanoma have decreased growth in mice with 
endothelial Nrp2 deficiency. However, decreased tumor growth was not observed in all 
tumor cell lines. For example, the growth of Lewis Lung carcinoma and T241 
fibrosarcoma were not inhibited in Nrp2 deficient mice, meaning that Nrp2 was not 
required for tumor growth all the time. Therefore, our study focused on Nrp2 in mouse 
pancreatic tumor could help elucidate the role of Nrp2 in angiogenesis and tumor 
progression of pancreatic cancer. According to previous results, we hypothesized that 
knocking down Nrp2 expression on endothelial cells inhibited pancreatic tumor growth 
and decreased tumor-derived angiogenesis in mice. 
Knowing that SEMA3F competitively inhibits the binding of an angiogenic factor 
VEGFA to NRP2, and that SEMA3F-NRP2 complex could affect the mobilization of 
actin filaments, we hypothesized that additional exogenous SEMA3F could inhibit 
tumor-associated angiogenesis and tumor progression. 
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MATERIALS AND METHODS 
 
In Vitro Cell Culture 
This study focused mainly on adenocarcinoma in pancreas, and therefore all the 
cell lines used were derived from PDAC origins of different species. Other cell lines were 
also investigated to gain more understanding in the study of pancreatic cancer. All cell 
lines were cultured in vitro in 10 centimeter (cm) tissue culture dishes with 10 microliter 
(mL) complete cell culture media using aseptic techniques, incubated at 37oC with 5% 
carbon dioxide. Cell media was changed every other day. 
 
Human PDAC Cell Lines 
Human PDAC Cell lines, including AsPC-1, BxPC-3, Capan-1, HPAF-II, MIA 
PaCa-2, and PANC-1 were originally obtained from American Type Culture Collection 
(ATCC). AsPC-1 cells were derived from nude mouse xenografts initiated with cells 
from ascites of a metastatic site of pancreatic cancer from a 62-year-old Caucasian 
female. AsPC-1 cells were cultured in RPMI 1640 media (Gibco). 10% fetal bovine 
serum (FBS) and 1% Penicillin-Streptomycin-Glutamine (PSG) (Gibco) were added to 
make complete growth media. BxPC-3 cells, a tumorigenic cell line with epithelial 
morphology, were derived from pancreatic adenocarcinoma of a 61-year-old female and 
maintained in RPMI 1640 (Gibco) with 10% FBS and 1% PSG of the final volume in in 
vitro cell culture. Capan-1 is another pancreatic tumor cell line with epithelial 
morphology that was derived from a pancreatic adenocarcinoma metastatic site in the 
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liver of a 40-year-old Caucasian male. This cell line was provided by Dr. Bruce Zetter 
from the Boston Children’s Hospital (BCH). In addition to the base medium Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco) and 1% PSG, 20% FBS of the final volume 
was used to support the in vitro cell growth of Capan-1. HPAF-II was kindly provided by 
Dr. Dipak Panigrahy from Beth Israel Deaconess Medical Center. HPAF-II has epithelial 
morphology and it was originally derived from pancreatic adenocarcinoma in a 
Caucasian male at the age of 44. Different to most other human PDAC cell lines, HPAF-
II requires Minimum Essential Medium (MEM) (Gibco) as the base medium, which 
already includes L-glutamine, and 10% FBS plus 1% PSG. MIA PaCa-2, obtained from 
Dr. Roopali Roy from BCH, assumes both adherent epithelial and round floating cell 
morphology. According to ATCC’s website, MIA PaCa-2 was directly derived from 
tumor tissue of the pancreas of a 65-year-old Caucasian male. 10% FBS and 1% PSG 
were used in addition to the DMEM cell medium. Although the ATCC website 
recommends using 2.5% horse serum, it was not included in the cell culture of MIA 
PaCa-2 in this study. MIA PaCa-2 cells required immediate splitting as soon as they were 
60-70% confluence, or all cells would float off from the bottom of the tissue culture dish. 
Another epithelial-like human PDAC cell line PANC-1 was derived from a 56-year-old 
Caucasian male. It was cultured in DMEM with 10% FBS and 1% PSG in vitro.  
 
Murine Pancreatic Tumor Cell Line 
Panc0H7 is a mouse PDAC cell line that was originally derived from carcinogen-
treated C57Bl6 mice and was kindly provided by Dr. Keping Xie from M.D. Anderson 
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Cancer Center in Texas (B. Wang et al., 2003). Panc0H7 requires 10% FBS and 1% PSG 
in addition to the DMEM base medium for continuous in vitro culture. Regular DMEM 
with D-glucose concentration of 1 g/L was not sufficient in supporting efficient 
proliferation of Panc0H7 cells. Therefore, DMEM with high D-glucose concentration of 
4.5 g/L was used instead. 
 
Other Cell Lines 
HEK293A cells are immortalized cells used for adenovirus propagation. 
HEK293A cells were originally purchased from ATCC and were kindly provided by Dr. 
Rosalyn Adam from the Urology Department at BCH. They were maintained in high 
glucose DMEM with D-glucose concentration of 4.5 g/L, with 10% FBS, 1% PSG, and 
1% MEM Non-Essential Amino Acid (NEAA) (Gibco). TRT cells are uroepithelial cells 
immortalized with human telomerase reverse transcriptase (hTERT). TRT cells were 
used to test the bioactivity of adenovirus. TRT cells were maintained in DMEM, 10% 
FBS, 1% PSG, 1% NEAA, and 0.1% thioglycerol. Another cell line used for testing the 
function of adenovirus, HaCat, was incubated in base medium MEM, 10% FBS, and 1% 
PSG. T241, Lewis Lung Carcinoma (LLC), EO771, and B16F10 are mouse-origin 
fibrosarcoma, lung carcinoma, breast tumor, and melanoma cells, respectively. Lysates of 
these cell lines from previous lab members were used to conduct our research. Porcine 
Aortic Endothelial (PAE) cells have low expressions of both NRP1 and NRP2 and served 
as a negative control cell line. Previous lab members had transfected PAE cells with 
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NRP1 and NRP2, which gave rise to PAE1 and PAE2 cells, serving as positive control 
cells for NRP1 and NRP2, respectively.  
 
Cell Subculture  
All cell lines were splitted at 80% to 90% confluence except one human PDAC 
cell line MIA PaCa-2, which required immediate splitting after 60-70% confluence was 
reached. After removing cell culture media, 2 mL of 0.05% trypsin-
Ethylenediaminetetraacetic Acid (EDTA) (Gibco) was applied to each 10cm tissue 
culture dish and incubated at 37C and 5% carbon dioxide for 5 minutes or until most cells 
detached from the bottom of the tissue culture dish. 10mL of complete cell media was 
added to stop the enzyme function of trypsin immediately after incubation. After 
transferring the mixture of the detached cells, 2 mL of trypsin-EDTA, and 10 mL of 
complete cell media were transferred to a 15 mL or 50 mL polypropylene conical tube 
(Falcon). Five minutes of centrifugation at 1000 revolutions per minute (rpm) allowed the 
cells to aggregate at the bottom of the conical tube. Supernatant was removed, and fresh 
complete cell media was added. Aspirating up and down several times helped achieve 
even distribution of cell suspension. A 1:3 or 1:4 splitting ratio was used to split cells into 
new 10 cm tissue culture dishes for maintaining continuous cell culture.  
 
Cell Cryopreservation 
All cell lines were cryopreserved in the gas phase of liquid nitrogen. When 
cryopreserving the cell lines, cell media used for in vitro culture was aspirated by 
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vacuum, followed by addition of 2 mL of trypsin-EDTA to detach the cells from each 10 
cm tissue culture dish. After incubating at 37oC for 5 minutes, 10 mL of fresh cell media 
was added to neutralize the enzyme action of trypsin-EDTA, and the mixture of detached 
cells, 2 mL trypsin-EDTA, and 10 mL complete cell media were transferred to a 15 mL 
or 50 mL polypropylene conical tube (Falcon). Supernatant was removed after 
centrifuging for 5 minutes. The cryopreservation media consists of 70% cell culture 
media, 20% FBS in addition, and 10% dimethyl sulfoxide (DMSO). DMSO was added to 
prevent cell death during the process of cryopreservation by reducing ice formation. A 
final volume of 1 mL of the cryopreservation medium with cells was loaded to each 
cryovial. Cryovials were stored in a Mr. Frosty Freezing Container overnight at -80oC 
before they were transferred to the liquid nitrogen tank. 
 
Adenovirus Propagation 
The recombinant protein production of SEMA3F proteins took place in human 
adenovirus serotype 5 (Ad5). Ad5 is a therapeutic adenovirus that lacks E1 and E3 early 
viral genes (Kovesdi & Hedley, 2010). The replication-incompetent (-E1/-E3) virus can 
successfully infect cells without further viral reproduction. Therefore, we used the 
HEK293A cells for Ad5 propagation, because HEK293A cells express the E1 gene 
products, which encode for proteins necessary to initiate the viral life cycle (Kovesdi & 
Hedley, 2010). The adenovirus propagation was a 10-day process starting from seeding 
two 10 cm tissue culture dishes with 1.5*106 HEK293A cells per dish in 10 mL media, 
and two 15 cm tissue culture dishes with 3.0*106 cells per dish in 20 mL media on day 1. 
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On day 3, one of the 10 cm dishes prepared on day 1 was infected with low titer viral 
supernatant, kindly provided by Dr. Rosalyn Adam from the Urology department at 
BCH. On the same day, another 15 cm dish was plated with 1.5*106 HEK293A cells with 
20 mL media. Twelve 15 cm culture dishes were seeded with 3.0*106 cells/dish in 20 mL 
media per dish, which were cultured to expand the population of HEK293A cells for later 
infection. On day 6, conditioned media from the 10 cm dish infected on day 3 was 
harvested. Mechanical force by aspirating the cell media up and down using a serological 
pipet helped detach the HEK293A cells, which contained adenovirus inside, from the 
bottom of the culture dish. To break the cell membranes and allow the virus to be 
released into the media, the harvested conditioned media was transferred to a 50 mL 
polypropylene conical tube (Falcon) and the tube was frozen on dry ice and thawed in 
37oC water bath three times. 100% ethanol could be added to dry ice to facilitate freezing 
by increasing the contact area between dry ice and the collected infectious media. Ice 
crystals formed in cytoplasm extruded cell membranes and caused the release of 
adenovirus into the harvested media. Centrifuging at 2500x gravity (g) allowed the cell 
debris to aggregate at the bottom of the conical tube. Supernatant containing adenovirus 
was collected for further viral infection. 1 mL of the supernatant was combined with 14 
mL fresh media and was used to change the media of the 15 cm culture dish plated on 
day 3. The remaining supernatant was frozen in 1 mL aliquots at -80oC , used for later 
infection after day 6. The infectious media from the 15 cm dish infected on day 6 was 
collected on day 8. After three times of freeze-thaw, the conditioned media was 
transferred to a 50 mL conical tube (Falcon) and centrifuged at 2500x g for 15 minutes. 
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About 13 mL supernatant could be yielded. 6 mL media from each of the twelve 15 cm 
tissue culture dishes was removed, and 1 mL of the collected supernatant was used to 
infect each 15 cm dish seeded on day 5. On day 10, the infectious media from the twelve 
15 cm dishes was harvested and pelleted at 1500 rpm for 5 minutes. Every 50 mL conical 
tube could hold infectious media from three 15 cm dishes with about 15 mL from each 
dish. Therefore, about 45 mL infectious media was collected in each conical tube. 35 mL 
was removed from each 50 mL conical tube, leaving about 7 mL conditioned media in 
the tube. After using a 10 mL serological pipette to aspirate the pellet up and down in the 
conical tubes, the tubes containing crude adenovirus were stored at -80oC for later 
process. Before purification, the infectious media experienced three times freeze-thaw 
followed by centrifugation at 2500x for 15 minutes. The supernatant was collected and 
stored as crude adenovirus.  
 
Adenovirus Purification 
The purification of adenovirus required the Fast-Trap Adenovirus Purification and 
Concentration Kit that contained several filters and removed impurities based on size and 
affinity. All filters were connected to vacuum source to facilitate filtration. The first step 
involved removal of contaminating deoxyribonucleic acid by adding 1 uL of Benzonase 
nuclease for each 10 mL of crude adenovirus. Mixed thoroughly, the capped conical 
tubes were incubated at 37oC for 30 minutes. The Benzonase nuclease treated crude 
adenovirus was then filtered through a Steriflip-HV filter to remove chunky impurities. 
After clarification, the clarified crude adenovirus was diluted 10 times with 10x Binding 
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buffer. The diluted crude adenovirus sample went down a Fast-Trap virus filter after the 
filter was equilibrated with 25 mL of Equilibration buffer. Theoretically, all of the 
adenovirus was bound to the Fast-Trap filter, and therefore the filtrate could be discarded. 
The adenovirus-bound Fast-Trap filter was washed by 20 mL of Wash buffer and eluted 
by 3 mL of Elution buffer. A second elution with another 3 mL of Elution buffer was 
optional. The last step of adenovirus purification was buffer exchange and concentrating. 
FBS in the crude adenovirus was removed and exchanged to phosphate buffered saline 
(PBS) after the buffer exchange to avoid immune response in in vivo injections. 1% 
glycerol was added optionally to avoid ice formation during virus storage.   
 
Virus Staining 
The virus titer of each propagation was determined by virus staining. We plated 
the HEK293A cells at 2.5*105 cells/mL and 0.5 mL per well on a 24-well plate. To obtain 
countable staining, we diluted the virus in PBS to 10-4, 10-5, 10^-6, and 10-7 of the original 
virus concentration and infected the HEK293A cells with 50 uL of each dilution per well 
after 24 hours of cell plating. After 48 hours of incubation at 37oC, the HEK293A cells 
were fixed by ice cold methanol for 20 minutes. Hexon proteins are found on the coat of 
adenovirus. Therefore, we incubated the infected HEK293A cells with the mouse anti-
hexon antibody from the Adeno-X Rapid Titer Kit (Clontech) for 1 hour at 37oC. After 
three washes in PBS with 3 minutes each, we tried the rat anti-mouse antibody as the 
secondary antibody coming from the same kit followed by 3,3-diaminobenzidine (DAB). 
However, this method did not yield quantifiable results. Therefore, we used the 1:200 
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PBS-diluted biotinylated anti-mouse antibody as the secondary antibody, incubated 1 
hour at 37oC on an orbital shaker, followed by avidin-horseradish peroxidase (HRP) to 
enhance the signal. HRP could convert chromogenic substrates, such as DAB, into 
colored products. 10x DAB was diluted 1:10 with 1x stable peroxidase buffer. Infected 
HEK293A cells turned brown after adding 250 uL of 1x DAB and dark spots were 
counted to determine the virus titer. Usually, the 10-5 infection provided the best staining 
and therefore was used for calculating the virus concentration using equation 1. 
[(infected cells/field)*(fields/well)]/[(volume virus)*(dilution factor)]    Eq.1 
Our virus propagation usually rendered us virus concentrations in the range of 1*109 to 
1*1010 infectious unit (IFU).  
 
Multiplicity of Infection (MOI) 
While virus titer indicated the number of virus we made, MOI was used to prove 
the functionality of the made virus. We plated the human TRT cells at 8,000 cells per 
well on a 12-well plate. Each well had 2 mL of cell media. After 24 hours of incubation 
at 37oC, 8*103, 8*104, and 8*105 IFU were used to infect the TRT cells. 30 uL of 
infectious media from each well was collected after 0, 24, 48, and 72 hours following 
viral infection. Collected infectious media and 6 uL of 6x Sodium Dodecyl Sulfate (SDS) 
reducing buffer per sample were boiled at 100oC for 7 minutes before they were loaded to 
a Western PAGE gel. Time response and dose response of viral infection were 
investigated on a Western blot to indicate if the virus was actively making SEMA3F. 
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Protein Lysis 
Protein lysates from tumor cells and other cell lines were obtained by lysing the 
cells. Cell media was removed by vacuum source. Ice cold PBS was used to wash off any 
cell media residue in the tissue culture dishes. After PBS was aspirated out, 500 uL of 
protein lysis buffer was added to a 10 cm tissue culture dish, or 250 uL of lysis buffer 
was added to each 5 cm dish. Every 50 mL of lysis buffer consists of 50 mL 
radioimmunoprecipitation assay (RIPA) buffer, which lyses cell membranes for protein 
extraction, and one EDTA-free Mini tablet (Sigma), which is a protease inhibitor cocktail 
that inhibits the degradation of intracellular proteins. Cells attached to the bottom of the 
tissue culture dishes were scraped off by a rubber scraper and were transferred with lysis 
buffer to a 2 mL Eppendorf tube. The Eppendorf tube was left on ice for 30 minutes to 
allow the breakdown of cell membrane. After 30 minutes, the Eppendorf tube was 
centrifuged at 10,000 rpm for 10 minutes in the cold room to allow cell debris to 
aggregate to the bottom. Supernatant was collected and stored at -20oC or -80oC.  
To obtain tissue lysates, tissues from mice such as ears and livers were collected 
and frozen in liquid nitrogen immediately after mice were sacrificed. Frozen tissues were 
hammered into powder and transferred to a homogenizer with 2 mL of lysis buffer. After 
further grinding using a homogenizer, the homogeneous tissue suspension was 
transferred to a 2 mL Eppendorf tube. Leaving the tube on ice for at least 30 minutes, the 
tube was spun down at 10,000 rpm for 10 minutes. Supernatant was collected and stored 
at -20oC or -80oC. An alternative approach to homogenize tissue was to use silicon beads 
and shear stress provided by a Fastprep-24 5G homogenizer (MP Biomedical) to 
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homogenize tissue into lysis buffer. Supernatant after centrifuging at 10,000 rpm for 10 
minutes was collected and stored at -20oC or -80oC.  
 
Protein Assay 
Protein assay was used to determine the concentration of a protein lysate. 30 uL 
of distilled water was added to all column 4 wells except well 4 H on a 96 flat bottom 
well plate (Corning), labeled 1 to 12 horizontally and A to H vertically. 5 uL of bovine 
serum albumin (BSA) (Sigma) with concentration of 10 mg/mL was added to wells 1 to 3 
on row H. 30 uL of BSA was added to well 4G and mixed evenly. 30 uL of diluted BSA 
from well 4G was transferred to the well above to be further diluted. Repeat dilutions to 
the well above created serial dilutions of BSA concentration. For each row of the serial 
dilutions, 5 uL of the diluted BSA solution was transferred into corresponding wells in 
column 1 to 3. A doublet of 5 uL of each protein sample was added to empty wells. In a 2 
mL Eppendorf tube, 1000 uL of Protein Assay Solution A (Bio-Rad) and 20 uL of 
Protein Assay Solution S (Bio-Rad) was mixed evenly. 25 uL of Protein Assay Solution 
A+S and 200 uL of Protein Assay Solution B (Bio-Rad) were added to all loaded wells 
except column 4 wells. Five minutes of incubation was allowed before the 96-well plate 
was read by a VERSAmax microplate reader (Molecular Devices) at 750 nanometer 
(nm). Values of absorbance at 750 nm from wells loaded with BSA serial dilutions were 
graphed with corresponding concentrations of BSA in a scatter plot using Excel. An 
equation was generated based on the linear regression of the curve. This equation was 
used to calculate the concentration of each protein sample.  
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Affinity Columns  
To enhance signals of proteins not expressed at high levels, we used affinity 
columns to purify and concentrate desired proteins. Concanavilin A (ConA) beads 
(Thermo Scientific) allows isolation of glycoproteins. NRP2 and SEMA3F are both 
glycosylated and therefore they could bind the ConA beads. 500 uL of ConA beads in 
stock buffer was taken by a 1000 uL pipet and prewashed with 1 mL PBS twice to get rid 
of the ethanol in the stock buffer. After the second wash, we equilibrated the ConA 
column with PBS to make a 50% ConA-PBS slurry. 1 mL of protein lysate, 72.6 uL of 5 
mole/liter (M) Sodium Chloride (NaCl), 2 uL of 500x Magnesium Chloride/Calcium 
Chloride buffer, and 50 uL of equilibrated ConA beads were incubated at 4oC overnight. 
On the second day, the ConA column was first washed with 1 mL of ConA first wash 
solution, which was consisted of NaCl at 0.4mM, 20 millimole/liter (mM) Tris buffer at 
pH 7.5, and 10% protein lysis buffer. The molarity of NaCl in the second wash was 
reduced to 50 mM while other ingredients were kept the same. Glycosylated proteins 
were then washed off from the ConA beads by boiling in 1x SDS reducing buffer for 10 
minutes at 100oC.   
 
Preparing the Western SDS PAGE Gel 
Western blot was used to separate proteins by size. Cell lysates and protein 
samples were loaded onto a 7.5% SDS PAGE gel with ten wells per gel. The gel is 
composed of two layers, a stacking layer on the top and a revolving layer on the bottom. 
The 7.5% resolving gel is made by liquid mixture of 3.75 mL of 30% acrylamide/0.8% 
		 38 
bis-acrylamide (National Diagnostics), 3.75 mL of 4x 1.5 M tris-Hydrogen Chloride 
(HCl)/0.4% SDS pH 8.8 (National Diagnostics), 7.5 mL of sterilized distilled water, 50 
uL of 10% ammonium persulfate (APS), and 10 uL of tetramethylethylenediamine 
(TEMED) (J.T. Baker Inc.). All components of the resolving layer were mixed as liquids, 
and the mixture was added to a thin chamber to solidify for approximately 30 minutes. To 
avoid air bubbles in the resolving layer, 0.5 mL of isopropanol was added on top of the 
liquid mixture. The stacking layer, composed of 30% acrylamide/0.8% bis-acrylamide, 
1.25 mL of 0.5 M tris-HCl/0.4% SDS pH 6.8 (National Diagnostics), 0.65 mL of 
sterilized distilled water, 25 uL of APS, and 5 uL of TEMED, was pipetted on top of the 
solidified resolving gel after discarding the isopropanol. A 10-well comb was 
immediately inserted to the stacking gel mixture. After solidifying for 30 minutes at room 
temperature, a wet paper towel was used to cover the top of the gel and the gel was stored 
at 4oC wrapped with aluminum foil if the gel was not used on the same day.  
 
Western Blot: Running and Transferring 
 Approximately 40 uL of protein sample could be loaded to each well of the SDS 
PAGE gel with 10 samples maximum. 20 uL of Precision Plus Dual Protein Dual Color 
Standards (Bio-Rad) with 5 uL of 6x SDS reducing buffer was used as the standard 
protein size indicator. Usually, same amount of protein was added to each well. 
Therefore, the volume of each protein sample was determined by the protein assay to 
normalize the difference that might be introduced by different concentrations of protein 
samples. The total amount of protein loaded was determined by the protein sample with 
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the lowest concentration. 6 uL of 6x reducing buffer was used with 30 uL of protein 
sample. If the protein sample was less than 30 uL, RIPA buffer was added to total the 
protein sample to 30 uL. All protein samples with reducing SDS buffer were loaded to 
Eppendorf tubes and boiled at 100oC for 5 to 10 minutes to allow the breakdown of 
tertiary structures of the proteins. While boiling the protein samples, we used a 200 uL 
pipet and aspirated up and down several times to clear the salts in the wells. The 
Eppendorf tubes were immediately transferred to ice to avoid protein denature. After 
loading the protein samples into the wells on the gel, 1x running buffer, diluted form 10x 
running buffer (Boston BioProducts), was added to a plastic bucket with the loaded gel. 
100 volts (V) was added for 1.5-2 hours. Once resolved, proteins were transferred from 
the SDS PAGE gel to either a nitrocellulose membrane or a Polyvinylidene difluoride 
(PVDF) membrane. The hydrophobic PVDF membrane was required to be wetted in 
100% methanol for 3-5 minutes before it was wetted in the 1x transfer buffer. However, 
the nitrocellulose membrane was relatively more hydrophilic and therefore it could be 
directly wetted in the 1x transfer buffer. The 1x transfer buffer was diluted from the 10x 
transfer buffer stock (Boston BioProducts) with 20% methanol added. A total 600 
milliJoules (mJ) was transferred form the gel to the membrane. In other words, if 300 
milliAmps (mA) was used for transfer, total transfer time would be 2 hours. If the 
transfer was set to 60mA, a 10-hour overnight transfer could take place at 4oC.  
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Western Blot: Membrane Blocking, Antibody Blotting, and Developing 
 After transfer, the membrane was blocked in 10 mL of 5% milk for one hour at 
room temperature. The 5% blocking milk was made by 0.5 gram of non-fat dry milk 
blotting grade blocker (BioRad) in 10mL of 1x Tris Buffered Saline (TBS) with 0.1% 
Tween 20 (Sigma) at pH 7.4. The membrane was then incubated in primary antibody 
diluted at 1:1000 in TBS with 0.1% Tween 20 (TBS-T) for 2 hours at room temperature 
or overnight at 4oC. After washing in TBS-T three times with 10 minutes each, the 
membrane was then incubated in the corresponding HRP conjugated secondary antibody 
diluted at 1:3000 in TBS-T for 1 hour at room temperature. The membrane was washed 
in TBS-T three times with 10 minutes each time. Blotted membranes were immersed in 
1:1 Oxidizing Reagent and Enhanced Luminol Reagent from the Western Lighting Plus-
ECL kit (Perkin Elmer) for 2 minutes, and then signals were captured and developed by 
HyBlot CL autoradiography films (Denville Scientific) in the dark room. 
 
Western Blot: Membrane Stripping and Reprobing 
 Primary and secondary antibodies on the membranes could be taken off by 
Stripping Buffer (Thermo Scientific). Membranes needed to be blotted with different 
antibodies could be washed in 10 mL of TBS-T for 5 minutes, followed by stripping by 5 
mLof  Stripping Buffer on a rocker for 5-10 minutes. The stripped membrane was them 
washed twice in 15 mL of TBS-T for 10 minutes each before it was blotted by another 
primary antibody. Membrane stripping and reprobing were useful when different proteins 
with similar protein sizes were investigated among the same protein samples.  
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Genotyping 
 Wild type (WT), heterozygous (HET), and knockout (KO) mice were used to 
investigate the roles of Nrp2 in vivo in our study. WT, HET, and KO mice express 
Nrp2+/+, Nrp2+/-, and Nrp2-/-, respectively. Although the KO mice are slightly smaller than 
the WT and HET mice in size, the difference was not obvious enough to be observed 
without further genotyping. Therefore, we cut a piece from the ears of each mouse to 
determine the type of the mouse. Since a GFR sequence was knocked in as the Nrp2 
sequence was knocked out, ear pieces from WT mice were not fluorescent under 
microscope. However, samples from both HET and KO mice fluorescent and thus were 
not able to be distinguished under microscope. Therefore, the gene sequences from HET 
and KO samples were genotyped by Transnetyx. Negative results of Nrp2 sequence 
indicated KO mice and positive results corresponded to HET mice. 
 
In Vivo Cell Injection 
 Orthotopic and subcutaneous injection of Panc0H7 cells were used in our study. 
Cells used for in vivo injection were first trypsinized from 10 cm cell culture dished by 2 
mL of trypsin-EDTA for 5 minutes at 37oC. The enzymatic function of trypsin was then 
neutralized by 5 mL of complete cell medium. Cells were centrifuged at 1000 rpm for 5 
minutes and supernatant was removed. Panc0H7 cells were suspended in 10 mL of 
Hank’s Balanced Salt Solution (HBSS) and were counted. The cells were then 
centrifuged again at 1000 rpm for 5 minutes to remove any trace of FBS, which might 
induce allergic reactions in C57BL/6 mice. After aspirating out the supernatant of the 
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second centrifugation, the Panc0H7 cells were suspended in HBSS at 1 million cells per 
100 uL HBSS for subcutaneous injection or at 1 million cells per 40 uL HBSS for 
orthotopic injection. 50% matrigel by volume was added to facilitate cell growth if 
needed. 
 
Paraffin Staining  
The formalin-fixed paraffin-embedded (FFPE) sections were stained with a pan-
endothelial cell marker, CD31 (also called platelet endothelial cell adhesion molecule-1, 
PECAM1) for the investigation of vasculature in pancreatic tumors. FFPE sections were 
first heated at 60oC for 10 minutes to remove any trace of water between pancreatic tissue 
and paraffin. De-paraffinization was carried out by immersing the slides in xylene for 4 
minutes, followed by another immersion in xylene for 2 minutes. After removing the 
paraffin, slides were rehydrated in 2 times of 100% ethanol for 2 minutes each, 2 times of 
95% ethanol for 2 minutes each, 1 time of 70% ethanol for 2 minutes, 1 time of 50% 
ethanol for 2 minutes, followed by immersion in PBS for 5 minutes to remove the 
ethanol. Antigen retrieval was performed by incubating slides in 20 ug/mL proteinase K 
for 20 minutes at room temperature. Proteinase K was washed off by PBS for three times. 
Following the antigen retrieval, the endogenous peroxidase was blocked by 3% hydrogen 
peroxidase in methanol for 12 minutes at room temperature. PBS was used to wash slides 
for three times. Trinitrobenzene (TNB) was used for blocking at room temperature for 30 
minutes. Rat anti-mouse CD31 was used as the primary antibody diluted at 1:100 in 
TNB. Incubated in the primary antibody overnight at 4oC, the slides were washed by Tris, 
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NaCl, and Triton (TNT) on the second day. Biotinylated anti-rat antibody was used as the 
secondary antibody diluted at 1:200 in TNB and it was applied to react with the primary 
antibody for 1 hour at room temperature. The secondary antibody was washed off by 
TNT for three times, followed by addition of streptavidin-horseraddish (SA-HRP) 
peroxidase diluted at 1:100 in TNB for 30 minutes at room temperature. Another TNT 
wash was applied. Biotinylated tyramide diluted at 1:50 in amplification buffer was 
added for 8 minutes. Another round of SA-HRP diluted at 1:100 was added for 30 
minutes at room temperature to enhance the signal of the staining. After washing with 
TNT for three times, DAB chromogen was added to turn blood vessels into brown. Slides 
were finally washed with water to remove any salts and were mounted with paramount 
for later blood vessel measurements. 
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RESULTS 
	
 The Importance of Nrp2 on the Tumor Endothelial Cell Compartment 
To investigate the role of Nrp-2 in pancreatic cancer, our in vivo model used both 
wild type (WT), heterozygous (HET), and knockout (KO) mice, which expressed Nrp-
2+/+, Nrp-2+/-, and Nrp-2-/- in vascular endothelial cells, respectively. As Nrp-2 serves as a 
coreceptor for VEGF with VEGFR-2, we hypothesized that the Nrp-2-VEGF-VEGFR-2 
complex induced angiogenesis in vivo, and therefore higher blood vessel density and 
more progressive tumor growth were expected to be associated with more Nrp-2 
expression on endothelial cells. We first examined whether a mouse PDAC cell line 
(Panc0H7) syngeneic to C57Bl/6 mice (since our Nrp-2 KO mice strain is in the C57Bl/6 
background) expressed the Nrp-2 receptor by isolating whole cell lysate protein and 
comparing on a western blot to other C57Bl/6 tumor cell lines including fibrosarcoma 
(T241), lung carcinoma (LLC), breast carcinoma (EO771), and melanoma (B16F10). 
Immunoblotting demonstrated that T241, LLC, EO771, B16F10, and Panc0H7 all 
expressed Nrp-2 protein, but to varying degrees (Figure 11). Protein isolated from Nrp-
2+/+ brain and Nrp-2-/- brain served as a positive and negative control, respectively. Beta-
actin served as a loading control.  
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To investigate the role of Nrp2 in pancreatic cancer, we injected 1 million 
Panc0H7 cells into Nrp2 WT, HET, and KO mice. Orthotopic injection of Panc0H7 cells 
into the pancreas allowed for local tumor growth in the pancreas and spontaneous tumor 
metastases to liver, spleen, and small intestine as well as ascites formation in the 
peritoneum. Our data indicated that Panc0H7 cells, a Nrp2-positive mouse pancreatic cell 
line, grew larger in Nrp2-intact animals as tumor weights in the pancreas were higher, 
with statistical significance (p<0.05), in WT mice than in KO mice (Figure 12). Tumor 
weights did not differ significantly between WT mice and HET mice (Figure 12). The 
liver weight was also significantly higher in WT mice compared to KO mice, suggesting 
Figure 11 | Mouse Neuropilin-2 Expression and Actin. T241, LLC, 
EO771, B16F10, and Panc0H7 all expressed Nrp2. WT brain served as 
the positive control while the KO brain was the negative control. 
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that the Panc0H7 cells had metastasized to the liver and increased its weight (Figure). 
However, no significant difference in spleen weights were observed among WT, HET, 
and KO groups (Figure 12). 
 
 
 
Figure 12 | A. Tumor Weight in Pancreas, Liver, and Spleen. The growth of 
Panc0H7 tumors were significantly inhibited (pin NRP-deficient mice in both pancreas 
and liver compare to wild type or NRP-2 heterozygous mice. However, the weight of 
metastatic tumors in spleen did not show statistical difference among mice with different 
levels of NRP-2 expression. B. Representative Photograph Depicting the Relative 
Sizes of Tumors in the Pancreas. Pancreatic tumors were grossly smaller in the Nrp-2 
KO mice than in the WT and Het groups, while no difference in pancreatic tumor sizes 
between the WT mice and the Het mice. Adapted from Ajmal, unpublished. 
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All increase in tissue mass is associated with an increase in blood vessel 
proliferation (Folkman, 1971). Therefore, we examined the vascular microvessel density 
in the pancreas tumors as a read-out of angiogenesis. Tumor vascularization was 
quantified by counting the number of blood vessels in pancreatic tumor tissue sections. 
The FFPE sections were stained with CD31, a pan-endothelial cell marker. CD31-
positive vessels were counted in high magnification (200x) bright field microscopic 
images. The results demonstrated that blood vessel density in the pancreas tumors in WT 
(n=3) and HET (n=2) mice were significantly higher than in pancreas tumors in KO 
(n=5) mice, with p values equal 0.0031 and 0.0017, respectively (Figure 13). No 
significant difference (p=0.2554) in pancreatic tumor blood vessel density was observed 
between WT and HET mice (Figure 13).
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Orthotopic pancreas tumor growth rates are difficult to evaluate over time since 
the tumor is inside the mouse, therefore in order to examine the rate of tumor growth in 
Nrp2 WT versus KO mice, we injected Panc0H7 cells subcutaneously on the dorsum. 
Figure 13 | Nrp2 is Required for Optimal Neovascularization in 
Pancreatic Cancer. The blood vessel density of pancreatic tumors in Nrp-2 
KO mice was significantly lower than that of Nrp-2 WT and HET mice, with 
p values equal 0.0031 and 0.0017, respectively, suggesting that there is 
significantly less angiogenesis in Nrp-2-deficient mice than WT and HET 
mice. There is no statistical difference (p=0.2554) in microvessel density 
between WT and HET mice.	
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While subcutaneous injection allowed longer life expectancy of the injected mice 
compared to orthotopic injection, metastases to other major organs were less likely to be 
observed within the time frame of our investigation. Our data showed that ectopic 
Panc0H7 tumors in Nrp2 KO mice weighed 42.5% less than ectopic Panc0H7 tumors in 
WT mice, and the volume of tumors was 52.9% smaller in KO mice compared to WT 
mice (Figure 14). The tumor volumes were calculated by equation 2. 
 
Tumor Volume = Tumor Length * Tumor Width * Tumor Width * 0.5         Eq.2 
 
 
 
 
 
	Figure 14 | Ectopic Pancreatic Cancer Growth is Nrp-2-Dependent. 
Subcutaneous Panc0H7 tumors were 42.5% smaller in Nrp2-deficient 
mice than tumors in the WT mice. 
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Developing a SEMA3F Adenovirus for Cancer Therapy 
Above we demonstrated that Nrp-2 expression in the host animal is essential for 
the optimal growth of tumor vessels and ultimately of overall tumor size and growth. Our 
data suggests that Nrp-2 is an important receptor needed for tumor angiogenesis, 
therefore targeting this receptor may be a viable therapy for pancreatic cancer. Nrp-2 is a 
unique receptor in that it binds both stimulatory (VEGF) and inhibitory (SEMA3F) 
ligands with equal affinity (Geretti et al., 2008). Therefore, SEMA3F protein can be used 
as a competitive inhibitor of VEGF binding. With no commercially available pure 
SEMA3F protein, a high concentration of SEMA3F loading would be hard to achieve in 
vivo. Therefore, we turned to therapeutic adenovirus with coding region for SEMA3F as 
a delivery vehicle in order to continuously produce SEMA3F in vivo.  
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Figure 15 | Ectopic Pancreatic Tumor Volume is Nrp-2-Dependent. 
Subcutaneous Panc0H7 tumors were 52.9% smaller in tumor weight in 
Nrp2-deficient mice than tumors in WT mice.  
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The therapeutic adenovirus serotype 5 we used in this study was replication-
incompetency due to the lack of the E1 gene region, which transcribes a viral factor 
required for inducing early genes necessary for viral replication (Kovesdi & Hedley, 
2010). Therefore, HEK293A cells, a cell line with the presence of E1 gene expression, 
were used to propagate the adenovirus. SEMA3F adenovirus of low titer was expanded in 
the HEK293A cells, and the conditioned media from culturing the infected HEK293A 
cells was collected. Amplified adenovirus resided in the HEK293A cells was released by 
cell membrane protrusion, achieved by freezing the thawing the conditioned media three 
times. The newly made adenovirus was then purified by filters based on size and affinity. 
The amount of purified adenovirus generated after amplification and purification 
was determined by the virus titer assay, which refers to the number of virus particles or 
infectious units (IFU). The virus titer of each propagation was determined by virus 
staining. Briefly, HEK293A cells infected with various dilutions of virus from 10-4 to 10-7 
were fixed and incubated with anti-Hexon primary antibody to detect infected cells and 
HRP-conjugated secondary antibody and then visualized with DAB chromogen, which 
turned infected HEK293A cells a dark brown color (Figrue 16).	The number of infected 
cells per 200x-power field were counted and he titer of the adenovirus was calculated by 
equation 3. Typically, the 10-5 infection provided the best quantification. Titers usually 
ranged from 109 to 1010 IFU. Virus titers of four propagations are summarized in Table 1. 
 
(infected cells/field) * (fields/well) / (volume virus in mL*dilution factor)      Eq. 3 
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Date of Propagation Virus Titer (IFU) 
8-28-2015 1.42*109 
11-13-2015 6.2*109 
1-8-2016 5.53*109 
1-8-2016 7.20*109 
 
10
-6
 10
-5
 
Figure 16 | SEMA3F Adenovirus is Infectious. Positively stained adenovirus-infected cells 
turned brown. An example of 10-6 and 10-5 infection is shown in the figure. 10-5 infection had 
more positively stained HEK293A cells than the 10-6 infection.  
Table 1 | Summarization of the Titers of 4 Propagations of SMEA3F 
Adenovirus. The titers of four cycles of SEMA3F adenovirus propagations 
are summarized in the table. The calculations of 4 titers of the SEMA3F 
adenovirus were all based on the 10-5 infection. 
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Adenovirus MOI 
 While virus titer assays were used to analyze the number of viral particles per 
volume, live or dead, the bioactivity or functionality of the propagated adenovirus was 
determined using an MOI assay. Virus of doses 8*104, 8*105, and 8*106 IFU were used to 
infect an hTERT (the catalytic domain of telomerase)-immortalized human bladder 
epithelial cell line called TRT-HU1 cells. Bioactivity of the adenovirus was confirmed by 
detecting virus-made SEMA3F protein in the conditioned media. The viral-produced 
SEMA3F is additionally tagged with histidine to enable its detection separate from 
endogenous SEMA3F protein. Conditioned media was collected from TRT-HU1 infected 
cells after 0, 24, 48, and 72 hours and SEMA3F protein was detected by immunoblotting 
with anti-SEMA3F or anti-histidine antibody. Conditioned media with bioactive 
adenovirus showed bands with gradually increased intensity in Western blots as time or 
infectious power increased, confirming the propagated adenovirus was actively making 
SEMA3F in a dose- and time-dependent manner (Figure 17).
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While anti-histidine antibody only detects virus-encoded SEMA3F as virus-
encoded SEMA3F has histidine tags, anti-SEMA3F detects all SEMA3F proteins in the 
conditioned media, including endogenous SEMA3F. The same Western membrane 
incubated with anti-histidine antibody was stripped and reprobed with anti-SEMA3F 
antibody, stronger band intensity with similar trend was observed (Figure 17).  
 
Time Response  Anti-Histidine 
Anti-SEMA3F 
Dose Response 
Anti-Histidine 
Anti-SEMA3F 
Figure 17 | SEMA3F Adenovirus is Functional. The SEMA3F adenovirus actively made 
SEMA3F protein blotted with anti-histidine or anti-SEMA3F antibody. The expression of 
SEMA3F increased with time or dose of adenovirus. Pure SEMA3F (45 ng) protein was 
loaded as the positive control. 
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In Vivo Bioactivity of SEMA3F Adenovirus  
Following the MOI assay, the in vivo functionality of SEMA3F was tested to 
demonstrate that the SEMA3F adenovirus was actively making SEMA3F protein in mice. 
SEMA3F recombinant adenovirus was injected into mice through tail veins and became 
systemically available after injection. Active SEMA3F protein was detected from liver 
lysates from 6 days to 12 days following the systemic injection of the SEMA3F 
adenovirus (Figure 18). 
 
 
 
 
 
 
 
95 kDa- 
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Active SEMA3F 
Figure 18 | Active SEMA3F was Detected in Liver Lysates. 
Active SEMA3F protein was detected from liver lysates at 95kDa 
in Western blot. This figure demonstrated the bioactivity of 
SEMA3F adenovirus in vivo, as active adenovirus-encoded 
SEMA3F protein was detected in the liver from day 6 to day 
following the systemic injection of adenovirus. Adapted from 
Lukianov, unpublished.  
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SEMA3F Adenoviral Therapy in Pancreatic Cancer – Prevention Trial 
 To investigate the potential anti-angiogenic or anti-tumor effect of viral-encoded 
SEMA3F in in vivo tumor growth, mice were injected systemically (intravenoulsy) with 
either control (n=4) or SEMA3F adenovirus (n=5). Three days after viral infection, 0.5 
million Panc0H7 cells were injected orthotopically into the pancreas. All treated mice 
were sacrificed 17 days after tumor injection. One mouse from each group died 
unexpectedly before tissue collection. Pancreas, liver, and spleen were harvested and 
weighed from each mouse and then fixed in formalin and embedded in paraffin for 
histological analysis. Mice treated with SEMA3F adenovirus had significantly smaller 
pancreas tumors as compared to that of mice treated with control adenovirus, with P 
value of 0.029 analyzed with one-tail student’s t test (Figure 19).
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Next, we analyzed the microvessel density (MVD) in the pancreas tumors from 
mice infected with control or SEMA3F adenovirus. As described above, MVD was 
determined by CD31 immunostaining. No statistical difference in MVD was observed 
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Figure 19 | Systemic SEMA3F Therapy Inhibited Pancreatic Tumorigenicity. The tumor 
weights of spleen, pancreas, and liver from Ad-control and Ad-SEMA3F were averaged and 
graphed. The weight of pancreatic tumors of the Ad-SEMA3F treated mice was significantly 
smaller (p=0.029) than that of the Ad-control treated mice. Spleen and liver weights did not 
show statistical difference between the Ad-control and the Ad-SEMA3F treated groups. 
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between the two groups. Both control and SEMA3F adenovirus-treated group had 
approximately 48 blood vessels per 200x field (Figure 20). However, the total tumor 
volume and hence tumor weight was greater in the control-treated mice than in SEMA3F-
treated mice. Therefore, SEMA3F inhibited angiogenesis in the pancreas tumors 
inhibiting their overall growth rate. 
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Figure 20 | SEMA3F does not Inhibit MVD in Pancreatic Tumors. The blood 
vessel density of each 200x microscopic field is approximately 48 for both the Ad-
control and the Ad-SEMA3F treated mice. No statistical difference was observed 
between the two groups. 
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To analyze the effect of SEMA3F on pancreatic tumor metastasis, the liver 
weights and liver histology was compared between the groups. The weight of the livers in 
the control adenovirus group was slightly but not significantly larger than the SEMA3F-
treated group (p=0.282). Furthermore, no obvious gross liver metastasis was observed by 
eye in either control or SEMA3F adenovirus-treated mice during necropsy. However, 
hematoxylin and eosin staining of liver sections revealed micrometastases in and around 
hepatic blood vessels in the control adenovirus-treated group but not in the SEMA3F 
adenovirus-treated group (Figure 21). Taken together, these data suggest that SEMA3F is 
effective at inhibiting tumor angiogenesis, tumorigenicity and metastasis of pancreatic 
cancer in prevention trials. 
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Figure 21 | Pancreatic Cancer Metastasizes to the Liver in Control Adenovirus-Treated 
Mice. Micrometastases invading hepatic vessels were seen in the Ad-control treated mice but 
not in the Ad-SEMA3F treated mice, 17 days after orthotopic injection of 0.5 million of 
Panc0H7 cells into pancreas with 50% matrigel. 
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In a separate experiment in which we injected twice as many Panc0H7 tumor cells 
(1 million), obvious gross metastases were visible in the livers of control mice after 13 
days. Hematoxylin and eosin sections of these livers revealed large metastases (Figure 
22). We plan to conduct future studies to examine the effects of SEMA3F therapy in 
prevention trials using this higher dose of tumor inoculation. 
 
 
 
 
Figure 22 | Panc0H7 Pancreas tumors Metastasize to the Liver. Obvious metastasis was 
observed under 40x (left) and 200x (right) microscopic images of hematoxylin & eosin 
sections. Metastasis on the tip of the liver took place 13 days after orthotopic injection of 1 
million Panc0H7 cells without matrigel into the pancreas of an untreated WT mouse.   
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DISCUSSION 
Nrp-2 Expression on Vascular Endothelial Cells 
  We observed that both the growth and the tumor-associated angiogenesis of 
Panc0H7 tumors were inhibited in the KO mice compared to those of the WT mice. 
Partially consistent with the observations for B16F10 melanoma, Nrp-2 has a significant 
role inducing tumor growth and angiogenesis in both Panc0H7 and B16F10 tumors as 
larger tumors were harvested from the WT mice compared to the tumors collected from 
the KO mice. However, in the KO mice, the B16F10 tumors were more efficiently 
suppressed up to 17 days following the injection of B16F10 tumor cells, while the growth 
Panc0H7 tumors was inhibited, but not completely suppressed in the KO mice. In 
contrast, the tumor growth of T241 (fibrosarcoma) and LLC (Lewis Lung carcinoma), 
were not inhibited in the endothelial Nrp-2-deficient mice.  
T241, LLC, B16F10, and Panc0H7 cells all express transmembrane Nrp-2 on the 
tumor cells (Figure 11). However, in the endothelial Nrp-2 deficient mice, we observed 
different degrees of inhibition on tumor growth of these cell lines. Previously, it was 
observed in immunohistologies that in the wild type mice injected with B16F10 tumor 
cells, Nrp-2 was later found upregulated in the vascular endothelial cells of the tumor-
derived vessels. However, no upregulation in Nrp-2 expression was observed in the 
endothelial cells of the T241 or LLC tumor-associated vessels in the wild type mice. In 
other words, the observations lead to the conclusion that the expression of Nrp-2 on 
endothelial cells is associated with more progressive tumor growth. Therefore, one 
possible explanation for the partial inhibition of Panc0H7 tumor growth in the KO mice 
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is that endothelial Nrp-2 was upregualted in the tumor-associated vessels in the wild type 
mice, but it was not the only VEGF receptor that was upregulated to induce tumor 
growth. Therefore, Nrp-2 expression on endothelial cells was important for the tumor 
growth as Panc0H7 tumors were larger in weight and volume in the WT mice compared 
to those in the KO mice, but Nrp-2 was not required for the growth of Panc0H7 tumors. 
Additional staining of Nrp-2 expression in Panc0H7 tumors will be needed to confirm 
this speculation. Furthermore, if Nrp-2 was not the only angiogenic receptor mediating 
tumor growth, there must be other receptors upregulated to facilitate tumor growth in the 
KO mice. Additional investigations on what other angiogenic receptors might be 
expressed during in vivo growth of Panc0H7 tumors will be helpful in better 
understanding the mechanisms of pancreatic tumor progression and developing curative 
treatments for pancreatic cancer.  
 
Reservoir Hypothesis  
 Elucidating the role of NRP-2 in angiogenesis and the signaling pathways of 
NRP-2 could also help develop treatment for PDAC targeting NRP-2. NRP-2 expression 
on tumor cells is associated with tumor-derived angiogenesis indirectly, although tumor 
cells do not have VEGFR on the cell membrane. The reservoir hypothesis hypothesizes 
that NRP-2 on tumor cells attracts and holds VEGF near the surface of the tumor cells at 
a high gradient (Figure 23) (Bielenberg, unpublished). Without the coreceptor VEGFR, 
VEGF bound to tumor NRP-2 do not pass down angiogenic signal directly. However, 
serving as a reservoir for VEGF, NRP-2 on tumor cells would trap VEGF and therefore 
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induce more vivid angiogenesis than tumors without NRP-2 expression once approached 
by blood vessels that express VEGFR (Figure 23) (Bielenberg, unpublished). It might 
lead to the observation that tumors with positive NRP-2 expression would grow more 
progressively. 
 
 
 
Figure 23 | The Reservoir Hypothesis of NRP-2 in Tumor Cells 
Induces Angiogenesis. The reservoir hypothesis suggests that cells 
with NRP2 expression on the surface act as a reservoir for VEGF at a 
high gradient. Trapped VEGF could lead to accelerated angiogenesis 
once in close proximity to blood vessels. Adapted from Bielenberg, 
unpublished. 
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NRP2 Expression in Human PDAC Cell Lines 
 It is important to confirm that human PDAC cell lines also express NRP-2 to 
develop curative treatment targeting NRP-2 for human pancreatic cancer in the future. 
Other researchers have shown that multiple human PDAC cell lines, including AsPC-1 
and BxPC3, express high levels of NRP-2 (Figure 5). However, we have not been 
successful in obtaining a western blot showing NRP-2 expression of human PDAC cell 
lines (Figure 24). The same membrane was reprobed to detect NRP-1 expression and β-
actin to confirm positive protein loading. We observed that multiple cell lines express 
high levels of NRP-1 except BxPC3 and Mia Paca 2 (Figure 24). Although it seems that 
NRP-1 plays a more significant role in human PDAC, NRP-1 would not be an ideal target 
in developing antitumor treatment. Impairment of NRP-1 expression during 
embryogenesis results in prenatal lethality (Fujisawa & Kitsukawa, 1998). Although 
NRP-1 was not as important in adulthood, it is reasonable to speculate that targeting 
NRP-1 might lead to more severe vasculature complications.  
To development treatments targeting NRP-2, we first need to confirm NRP-2 
expression in tumor cells. One possibility to improve the western blot for NRP-2 
exoression in human PDAC cell lines is to use concanavilin A (ConA) beads which could 
act as a ligand to bind a specific class of glycoprotein from complex protein samples that 
contain alpha-lined mannose or terminal glucose. ConA beads could bind NRP-2, which 
is a glycosylated protein, while other proteins ran through the ConA column. NRP-2 
could be recovered later by washing the ConA beads with high salt solutions. Another 
possibility to purify NRP-2 by an immunoprecipitation column. Protein G Sepharose 
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beads (Sigma) could bind human and rabbit immunoglobulin G (IgG). Incubating Protein 
G Sepharose beads with cells lysates of human PDAC, NRP-2 could be purified and 
concentrated while other proteins would be pulled down. Loading purified NRP-2 to an 
SDS-PAGE gel might lead to better Western blot results of NRP-2 expression in human 
PDAC cells.   
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Blood Vessel Density and Angiogenesis 
 No statistical difference in pancreatic tumor microvessel density was observed 
between the mice treated with control adenovirus or the SEMA3F adenovirus. However, 
this observation does not necessarily lead to the conclusion that there is no difference in 
tumor-derived angiogenesis between the two groups. Decreased angiogenesis could be 
observed with decreased, unchanged, and increased area microvessel density (Figure 25) 
(Hlatky, 2002). Angiogenesis could be quantified by multiplying the averaged 
Figure 24 | NRP-1 and NRP-2 Expressions in PDAC Cells. Expression of NRP-2 is 
low except HPAF-II moderately expresses NRP-2. The same membrane was reprobed 
for NRP-1, and it shows that AsPC-1, HPAF-II, Capan-1, and PANC-1 all express high 
levels of NRP-1. 
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microvessel density per area to the number of areas of the tumor. Harvested pancreatic 
tumors were significantly smaller in the SEMA3F-treated group than those in the control 
adenovirus-treated group, meaning that the tumors from the SEMA3F-treated mice had a 
smaller number of areas in the tumor due to the drop out of the tumor cells as well as the 
blood vessels, compared to the control group. Taken together, in the SMEA3F-treated 
group, unchanged area microvessel density and significantly smaller tumors together 
resulted in decreased angiogenesis.  
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Figure 25 | Microvessel Density Following Antiangiogenic Treatment could be 
Increased, Unchanged, or Decreased. Shrinkage in tumor size is a combination of 
capillary dropout and tumor cell dropout. Regression in tumor growth following 
antiangiogenic treatment could be reflected by increased, unchanged, or decreases 
microvessel density. Adapted from Hlatky, 2002. 
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Liver as a Bioreactor for SEMA3F 
 Liver metastases are commonly observed at advanced stages of pancreatic cancer. 
In addition, it is usually the tumor metastasis, not the primary tumor in the pancreatic 
cancer that leads to mortality. Targeting the tumor metastasis in the liver or preventing 
metastasis to the liver, if possible, would be tremendously helpful for developing a 
curative treatment for pancreatic cancer. There has not been any previous treatment that 
is found effective in inhibiting liver metastasis in the pancreatic cancer. However, our 
data suggested that micrometastases was inhibited in the SEMA3F-adenovirus-treated 
mice, while micrometastases was still observed in the control-adenovirus-treated group. 
We realized that adenovirus could be bridged to the liver through binding to the 
vitamin K-dependent coagulation zymogens, which are able to bind receptors in the liver 
(Baker et al., 2007). We have also detected active SEMA3F protein encoded by the 
recombinant adenovirus in the liver (Figure 18). These knowledge and observations lead 
to a conclusion that the liver would become a bioreactor for encoding active SEMA3F 
protein in vivo after SEMA3F-adenovirus is distributed systemically through the tail vein 
in mice. 
We demonstrated that adenovirus-encoded SEMA3F might inhibit pancreatic 
tumor growth and tumor-associated angiogenesis through the interaction with the NRP-2 
receptor. Therefore, using recombinant SEMA3F-adenovirus as a potential treatment for 
pancreatic cancer might more efficiently target the liver and inhibit liver metastasis. 
Effective liver metastasis inhibition might bring light in extending the time frame of 
survival for patients of pancreatic cancer. 
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Toxicity of SEMA3F 
 There is no established evidence related to the toxicity of SEMA3F. Since 
SEMA3F is an endogenous protein, we do not believe systemic SEMA3F would 
introduce severe toxic reactions in the body. We investigated the amount of endogenous 
SEMA3F with systemic bioavailability. Approximately 100ng endogenous inactive 
SEMA3F at 65kDa and 20ng active SEMA3F at 95kDa were detected from ear lysates of 
the WT mice (Figure 26). However, effects of high levels of active SEMA3F, encoded 
constitutively by SEMA3F-adenovirus, need to be studied in the future.  
 
 
 
 
 
 
Active SEMA3F  
 
Inactive SEMA3F 
Figure 26 | Endogenous SEMA3F from Ear Lysates. Approximately 100ng endogenous 
inactive SEMA3F and 20ng active SEMA3F were detected from whole ear lysates of a WT 
mouse. A gradient of pure SEMA3F protein was used to determine the level of endogenous 
SEMA3F.  
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As SEMA3F-adenovirus could be specifically bridged to liver, the level of 
SEMA3F in the liver is higher than that in the systemic circulation. However, from 
studying the tissue distribution of Nrp-2 in mice we found that normal liver does not 
express Nrp-2 (Figure 27). Therefore, the inhibitory effects carried out by SEMA3F 
would not disrupt the functions of normal liver without the presence of Nrp-2. This 
finding further highlights the advantage of SEMA3F as a therapeutic treatment since 
SEMA3F could potentially target cancerous tissue in the liver distinguishably from the 
normal tissue of the liver. However, high levels of Nrp-2  
expression in bladder shown by Western blot and staining of cryosections of Nrp-2+/LacZ 
mice with X-gal reagent and anti-alpha smooth muscle actin antibody, might contribute 
to side effects in bladder (Figure 28) (Bielenberg et al., 2012). Nrp-2, once bind 
SEMA3F, might potentially result in incontinency, or continuous contraction of the 
smooth muscle in the bladder (Bielenberg et al., 2012).  
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Figure 27 | Tissue Distribution of Nrp-2. Normal liver tissue does not express 
Nrp2. Lung, kidney, heart, and skin have very low level of Nrp2 expression. Nrp2 
has important roles in neuronal guidance, and therefore Nrp2 is expressed in brain. 
Bladder express very high level Nrp2, which might lead to side effects regarding 
treatments targeting Nrp2. Adapted from Bielenberg et al., 2012. 
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Figure 28 | Neuropilin-2 Expression in Nrp-2+/LacZ Mouse. A. X-gal 
staining (blue) of a cryosection of a newborn Nrp2+/LacZ mouse with eosin 
(pink) counterstain demonstrated tissue distribution of Nrp2. The bladder, 
marked with an asterisk, expressed high level of Nrp2 than other tissues. 
B. X-gal staining (blue) of a cryosection of an 8-week Nrp2+/LacZ mouse 
with eosin (pink) counterstain demonstrated Nrp2 expression in bladder. 
The smooth muscle layer expressed high level of Nrp2. C. A cryosection 
of an 8-week Nrp2+/LacZ mouse stained with anti-alpha smooth muscle 
actin antibody (brown) and counterstained with hematoxylin (blue) also 
confirmed Nrp2 distribution in the smooth muscle layer of bladder. 
Adapted from Bielenberg et al., 2012. 
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Future in vivo Experiments 
 In our in vivo experiments, we injected control-adenovirus or SEMA3F-
adenovirus three days prior to the injection of tumor cells. We demonstrated preventive 
injection of SEMA3F-adenovirus could lead to smaller primary pancreatic tumors and 
decreased angiogenesis. In the future, effects of intervention and regression by SEMA3F 
could be studied by injecting adenovirus after the orthotopic injection of tumor cells, but 
before metastasis takes place, and adenovirus injection after the occurrence of liver 
metastasis, respectively (Figure 29). Additional injection points of adenovirus might help 
further study the capacity and efficacy of SEMA3F as a therapeutic treatment for 
pancreatic cancer.  
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Figure 29 | Demonstration of Three Time Points of Adenovirus 
Injection. Preventive injection of adenovirus prior to orthotopic injection of 
tumor cells in pancreas, interventional adenovirus injection after occurrence 
of primary pancreatic tumor but before liver metastasis, and regressing 
injection of adenovirus after liver metastasis takes place could become three 
time points of adenovirus injection to investigate the efficacy of SEMA3F 
in treating different stages of pancreatic cancer.  
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CONCLUSION 
 
 Taken together, our study suggested that NRP-2 plays an important role in 
inducing tumor-derived angiogenesis and in vivo tumor growth, as we observed 
significantly decreased blood vessel density and significantly smaller Panc0H7 tumors in 
NRP-2-/- mice compare to NRP-2+/+ and NRP-2+/- mice. We also concluded that NRP-2 
could be a potential target for treating pancreatic tumors, since NRP-2 is pivotal in 
inducing angiogenesis. SEMA3F was proved to be efficient in reducing pancreatic 
tumors, where SEMA3F acted as a potential inhibitory ligand to NRP-2. Significantly 
smaller pancreatic tumors were harvested from NRP-2-/- mice compare to NRP-2+/+ mice. 
SEMA3F also inhibited total angiogenesis carried out by NRP-2 by inhibiting the binding 
of VEGF to NRP-2. Although SEMA3F-treated tumors had unchanged area blood vessel 
density compare to the control adenovirus, the total blood vessel density decreased in the 
SEMA3F-treated tumors. 
 Limitations of our study also exist. For example, increasing the number of 
subjects in in vivo studies would increase the accuracy of the conclusions and reduce 
variations in observations. In addition, we observed that NRP-2 played an important role 
in Panc0H7 tumors, but more experiments on other pancreatic tumor cell lines would be 
needed to make further conclusions on the roles of NRP-2 in pancreatic cancer in general. 
In the study of the efficacy of SEMA3F, adenovirus was used to deliver SEMA3F. 
However, we did not quantify the amount of SEMA3F protein made by the adenovirus 
per IFU. Measuring the quantity of adenovirus-encoded SEMA3F would help determine 
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the optimal dose of SEMA3F in reducing pancreatic tumors. Furthermore, while the roles 
of NRP-2 and SEMA3F in regulation tumor-derived angiogenesis were investigated in 
this study, their capacity in controlling lymphangiogenesis has not been well elucidated.  
 Therefore, our study proved that NRP-2 might be a promising target in future 
pancreatic tumor treatments. Nevertheless, further experiments, including the 
introduction of multiple injection points of adenovirus and investigating 
lymphangiogenesis, are needed to better elucidate the roles of NRP-2 in pancreatic cancer 
and the efficacy of SEMA3F as a potential treatment for pancreatic tumors. 
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